
    
      A phase I study (11-HMedIdeS-01, EudraCT no. 2012-000 969-21) first in man single ascending
      dose study in 29 healthy subjects to investigate if IdeS is safe and well tolerated in doses
      up to 0.24 mg/kg body weight (BW).
    
  